Interleukin-10 a prognostic factor in treatment with autologous melanoma vaccine

Scientists from the Kimmel Cancer Centre at Jefferson have found that interleukin-10 production in tumour cells is a possible prognostic factor in patients with advanced melanoma who are treated with autologous melanoma cell vaccine. They are presenting their data at the 2010 ASCO Annual Meeting in Chicago...

Read the whole article on

More from